BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 8040669)

  • 1. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report.
    Yang JC; Topalian SL; Parkinson D; Schwartzentruber DJ; Weber JS; Ettinghausen SE; White DE; Steinberg SM; Cole DJ; Kim HI
    J Clin Oncol; 1994 Aug; 12(8):1572-6. PubMed ID: 8040669
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2.
    Lindsey KR; Rosenberg SA; Sherry RM
    J Clin Oncol; 2000 May; 18(9):1954-9. PubMed ID: 10784637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An ongoing prospective randomized comparison of interleukin-2 regimens for the treatment of metastatic renal cell cancer.
    Yang JC; Rosenberg SA
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S79-84. PubMed ID: 9457400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.
    Weiss GR; Margolin KA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Gaynor ER; Boldt DH; Doroshow JH; Bar MH
    J Clin Oncol; 1992 Feb; 10(2):275-81. PubMed ID: 1732429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
    Rosenberg SA; Yang JC; Topalian SL; Schwartzentruber DJ; Weber JS; Parkinson DR; Seipp CA; Einhorn JH; White DE
    JAMA; 1994 Mar 23-30; 271(12):907-13. PubMed ID: 8120958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy.
    Fyfe G; Fisher RI; Rosenberg SA; Sznol M; Parkinson DR; Louie AC
    J Clin Oncol; 1995 Mar; 13(3):688-96. PubMed ID: 7884429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma.
    Guleria AS; Yang JC; Topalian SL; Weber JS; Parkinson DR; MacFarlane MP; White RL; Steinberg SM; White DE; Einhorn JH
    J Clin Oncol; 1994 Dec; 12(12):2714-22. PubMed ID: 7989949
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: the University of Chicago experience.
    Shulman KL; Stadler WM; Vogelzang NJ
    Urology; 1996 Feb; 47(2):194-7. PubMed ID: 8607232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of polyethylene glycol-modified interleukin-2 (PEG-IL-2) in the treatment of patients with metastatic renal cell carcinoma and melanoma. A phase I study and a randomized prospective study comparing IL-2 alone versus IL-2 combined with PEG-IL-2.
    Yang JC; Topalian SL; Schwartzentruber DJ; Parkinson DR; Marincola FM; Weber JS; Seipp CA; White DE; Rosenberg SA
    Cancer; 1995 Aug; 76(4):687-94. PubMed ID: 8625167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcome of high-dose bolus intravenous interleukin-2 with a modified administration schedule for Asian patients with metastatic renal cell carcinoma.
    Lee JY; Song C; Hong BS; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2017 Jan; 79(1):173-180. PubMed ID: 28011979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of metastatic renal cell carcinoma with high-dose bolus interleukin-2 in a non-intensive care unit: an analysis of 124 consecutively treated patients.
    Gitlitz BJ; Hoffman DM; Moldawer N; Belldegrun A; Figlin RA
    Cancer J; 2001; 7(2):112-20. PubMed ID: 11324764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of high-dose interleukin-2 either alone or in combination with interferon alfa-2b in advanced renal cell carcinoma.
    Atkins MB; Sparano J; Fisher RI; Weiss GR; Margolin KA; Fink KI; Rubinstein L; Louie A; Mier JW; Gucalp R
    J Clin Oncol; 1993 Apr; 11(4):661-70. PubMed ID: 8478661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
    Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
    Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hybrid high-dose bolus/continuous infusion interleukin-2 in patients with metastatic renal cell carcinoma: a phase II trial of the National Biotherapy Study Group.
    Dillman RO; Wiemann MC; Bury MJ; Church C; DePriest C
    Cancer Biother Radiopharm; 1997 Feb; 12(1):5-11. PubMed ID: 10851441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose intravenous bolus interleukin-2 with interferon-alpha therapy for metastatic melanoma and renal cell carcinoma.
    Karp SE
    J Immunother; 1998 Jan; 21(1):56-61. PubMed ID: 9456437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.
    Thompson JA; Shulman KL; Benyunes MC; Lindgren CG; Collins C; Lange PH; Bush WH; Benz LA; Fefer A
    J Clin Oncol; 1992 Jun; 10(6):960-8. PubMed ID: 1588376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy of renal cell carcinoma with interleukin-2 and lymphokine-activated killer cells: phase II experience with a hybrid bolus and continuous infusion interleukin-2 regimen.
    Parkinson DR; Fisher RI; Rayner AA; Paietta E; Margolin KA; Weiss GR; Mier JW; Sznol M; Gaynor ER; Bar MH
    J Clin Oncol; 1990 Oct; 8(10):1630-6. PubMed ID: 2213100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer.
    Marincola FM; White DE; Wise AP; Rosenberg SA
    J Clin Oncol; 1995 May; 13(5):1110-22. PubMed ID: 7738617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-year survival results in metastatic renal cell cancer patients treated with monoimmunotherapy with subcutaneous low-dose interleukin-2.
    Lissoni P; Bordin V; Vaghi M; Fumagalli L; Bordoni A; Mengo S; Bucovec R; Fumagalli E; Malugani F; Ardizzoia A; Giani L; Gardani GS; Tancini G
    Anticancer Res; 2002; 22(2B):1061-4. PubMed ID: 12168901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer.
    Kammula US; White DE; Rosenberg SA
    Cancer; 1998 Aug; 83(4):797-805. PubMed ID: 9708948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.